Metabolic diseases

#Autoimmune disease #Diabetes #Mergers and acquisitions #Metabolic diseases

Barinthus Bio and Clywedog Therapeutics announce merger

Immunology and inflammation company Barinthus Biotherapeutics and private company Clywedog Therapeutics will merge to target metabolic and autoimmune diseases, the companies have announced.  The combined company, named Clywedog Therapeutics, will now advance a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases. The portfolio includes three differentiated, clinical stage… Read More

#Business & Investment #News

Pascal Soriot, Chief Executive Officer, AstraZeneca
#AstraZeneca #Investment #Metabolic diseases #New facility #United States

AstraZeneca invests $50b in US, plans new chronic disease centre

AstraZeneca will invest $50 billion in the United States by 2030, following similar announcements by other big pharma companies.   The company says the investment will create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients… Read More

#Business & Investment #News

Weight loss concept
#GLP-1 #Metabolic diseases #Obesity #Protagonist Therapeutics #Weight loss

Triple agonist designed to outperform GLP-1 drugs for obesity

Protagonist Therapeutics has announced a new, highly potent oral triple agonist peptide development candidate for obesity.   With once-daily dosing, PN-477o targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors.  The company has announced it will also develop a subcutaneous version, PN-477sc, as… Read More

#News

Woman tests blood glucose level
#Diabetes #Drug targets #Metabolic diseases #Obesity #Queen's University Belfast #University of Glasgow #University of Pittsburgh

New discovery could advance drugs for diabetes and obesity

Scientists have unlocked new details on important ‘receptor’ proteins – promising targets for the creation of novel drugs for metabolic conditions ranging from diabetes to obesity and inflammatory disorders.  The discovery – led by the University of Glasgow, Queens University Belfast and the University of… Read More

#News

#Diabetes #Liver disease #Metabolic diseases #Obesity #Weight loss

New DDW Highlights podcast: 27 May 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this week focus on drug discovery for metabolic diseases, with a… Read More

#News

#Diabetes #Liver disease #Metabolic diseases #Obesity #Weight loss

This week in drug discovery (19-23 May) 

News round-up for 19-23 May by DDW Senior Digital Content Editor Diana Spencer. Our news highlights this week focus on drug discovery for metabolic diseases, with a number of developments in treatments for obesity, liver disease, and diabetes. The top stories: GSK buys… Read More

#News